Tokyo, March 25, 2011, Astellas Pharma Inc.  (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has established Astellas Pharma d.o.o. in Slovenia.

The regional management of Astellas’ South East European business will be located in Slovenia, and will be known as Astellas Pharma South East Europe. The details of the affiliate in which the regional management is based are as follows:
 
Name: Astellas Pharma d.o.o.
Established: December 2010
Location: Ljubljana, Slovenia 
Representative: Mr. Adam Pearson, General Manager
Businesses description: Marketing and distribution of pharmaceuticals, etc.
 
Additionally, Astellas has established wholly-owned subsidiary (Astellas d.o.o.) in Croatia.
Astellas has already established wholly-owned subsidiaries in Romania and Bulgaria in August 2009. Astellas South East Europe will manage the business in Romania and Bulgaria, as well as Slovenia, Croatia, and some operations in Bosnia-Herzegovina, as one regional organisation.
 
Astellas Pharma South East Europe will play a key role in driving Astellas’ growth in South East European countries. The organisation will focus on marketing and selling Astellas’ portfolio of innovative global products including Omnic®and OmnicOCAS® for the treatment of the functional symptoms of benign prostatic hyperplasia , Vesicare® for the treatment of overactive bladder, Protopic® for the treatment of atopic dermatitis and Prograf®/ Advagraf®, an immunosuppressant.
 
The establishment of Astellas Pharma South East Europe is an important step forwards in Astellas Pharma Europe’s ongoing programme of strategic geographical expansion and reflects the company’s commitment to introducing innovative and reliable pharmaceutical products that help to improve people’s lives around the world.